Cancer drug firm DARA regains stock compliance
Raleigh, N.C. —
The Raleigh company said that the Nasdaq notified the drug firm on Tuesday that it had regained compliance with listing requirements. The company lost compliance when its stock price fell below $1, the minimum price the exchange requires for a stock listing. DARA was trading at $1.03 per share this morning.
DARA focuses on oncology and oncology supportive care products. Late last year, the company launched Soltamox, a liquid version of the breast cancer drug tamoxifen. The company plans a launch of Gelclair, a gel that coats the surface of the mouth covering lesions caused by radiotherapy or chemotherapy.
Please Log In to add a comment.
Best of TechWire Insider
- Star Trek gets real: Durham startup delivers interactive holograms
- Every tech company needs to join 'Global Government Surveillance Reform' movement
- Durham entrepreneurs find ally in Charlotte medtech incubator
- GoGown deal shows power, necessity of networking for startups
- New GSK oncology consortium targets combination therapies
- Fighting hospital infections: A Durham nurse's dream produces the GoGown
- From photos to out-of-this-world art: Raleigh firm's software transforms images
- LabCorp expands gene tests for cancer - but don't confuse these with 23andMe
- ChannelAdvisor: Mobile cuts deeply into PC share of online shopping
- Inside Appia's latest funding deal: Debt beats dilution